Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

被引：1

作者：

Harbeck, Nadia

Nitz, Ulrike

Christgen, Matthias

Kates, Ronald E.

Braun, Michael Wilhelm

Kummel, Sherko

Schumacher, Claudia

Potenberg, Jochem

Malter, Wolfram

Augustin, Doris

Aktas, Bahriye

Forstbauer, Helmut

Tio, Joke

Kleine-Tebbe, Anke

Liedtke, Cornelia

de Haas, Sanne

Deurloo, Regula

Wuerstlein, Rachel

Kreipe, Hans Heinrich

Gluz, Oleg

机构：

[1] Univ Munchen LMU, Brustzentrum, Munich, Germany

[2] Evangel Hosp Bethesda, Breast Canc Niederrhein, Monchengladbach, Germany

[3] Hannover Med Sch, Hannover, Germany

[4] West German Study Grp, Monchengladbach, Germany

[5] Rotkreuzklinikum, Munich, Germany

[6] Kliniken Essen Mitte, Essen, Germany

[7] St Elisabeth Hosp Koln Hohenlind, Cologne, Germany

[8] Waldkrankenhaus Spandau, Dept Hematol, Berlin, Germany

[9] Univ Hosp Cologne, Dept Obstet & Gynecol, Cologne, Germany

[10] Klinikum Deggendorf, Deggendorf, Germany

[11] Univ Hosp Leipzig, Univ Hosp Essen, Essen, Germany

[12] Practice Network Hematol Oncol, Troisdorf, Germany

[13] Univ Hosp Muenster, Dept Gynecol & Obstet, Munster, Germany

[14] DRK Kliniken Berlin Kopenick, Berlin, Germany

[15] Charite Univ Med Berlin, Berlin, Germany

[16] F Hoffmann La Roche Ltd, Basel, Switzerland

[17] Ludwig Maximilians Univ Munchen, Munich, Germany

[18] Breast Ctr Niederrhein, Monchengladbach, Germany

[19] Univ Clin Cologne, Monchengladbach, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.572

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

572

引用

页数：1

共 50 条

[1] Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
Harbeck, Nadia
Gluz, Oleg
Christgen, Matthias
Braun, Michael Wilhelm
Kummel, Sherko
Potenberg, Jochem
Aktas, Bahriye
Schumacher, Claudia
Forstbauer, Helmut
Augustin, Doris
Kraemer, Stefan
Just, Marianne
Tio, Joke
Kleine-Tebbe, Anke
Liedtke, Cornelia
Kates, Ronald E.
Hofmann, Daniel
Wuerstlein, Rachel
Kreipe, Hans Heinrich
Nitz, Ulrike
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial
Graeser, Monika
Gluz, Oleg
Biehl, Claudia
Ulbrich-Gebauer, Daniel
Christgen, Matthias
Palatty, Jenci
Kuemmel, Sherko
Grischke, Eva -Maria
Augustin, Doris
Braun, Michael
Potenberg, Jochem
Wuerstlein, Rachel
Krauss, Katja
Schumacher, Claudia
Forstbauer, Helmut
Reimer, Toralf
Stefek, Andrea
Fischer, Hans Holger
Pelz, Enrico
zu Eulenburg, Christine
Kates, Ronald
Ni, Hua
Kolberg-Liedtke, Cornelia
Feuerhake, Friedrich
Kreipe, Hans Heinrich
Nitz, Ulrike
Harbeck, Nadia
CLINICAL CANCER RESEARCH, 2023, 29 (04) : 805 - 814
[3] Association between PIK3CA mutation status and development of brain metastases in HR+/HER2-metastatic breast cancer
Fitzgerald, D. M.
Muzikansky, A.
Pinto, C.
Henderson, L.
Walmsley, C.
Allen, R.
Ferraro, G. B.
Isakoff, S.
Moy, B.
Oh, K.
Shih, H. A.
Dias-Santagata, D.
Iafrate, A. J.
Bardia, A.
Brastianos, P. K.
Juric, D.
ANNALS OF ONCOLOGY, 2019, 30
[4] Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2-chemotherapy trial.
Gluz, Oleg
Nitz, Ulrike
Christgen, Matthias
Braun, Michael
Luedtke-Heckenkamp, Kerstin
Darsow, Maren
Forstbauer, Helmut
Potenberg, Jochem
Uleer, Christoph
Grischke, Eva-Maria
Aktas, Bahriye
Schumacher, Claudia
zu Eulenburg, Christine
Jozwiak, Katarzyna
Kates, Ronald E.
Graeser, Monika
Wuerstlein, Rachel
Kreipe, Hans Heinrich
Kuemmel, Sherko
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Early proliferation response stratified by recurrence score demonstrates distinct efficacy of different endocrine therapies in the prospective WSG-ADAPT HR+/HER2-trial run-in phase
Harbeck, N.
Gluz, O.
Wuerstlein, R.
Kuemmel, S.
Nuding, B.
Rezai, M.
Forstbauer, H.
Maass, N.
Kates, R.
Nitz, U.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S110 - S110
[6] PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2-breast cancer
Teran, Eduardo
Lozano, Rebeca
Rodriguez, Cesar A.
Abad, Mar
Figuero, Luis
Munoz, Jose Antonio
Cigarral, Belen
Rodrigues, Aline
Sancho, Magdalena
Gomez, M. Asuncion
Morchon, Daniel
Montero, Juan Carlos
Sayagues, Jose Maria
Ludena, M. Dolores
Fonseca, Emilio
CANCER MEDICINE, 2024, 13 (17):
[7] PIK3CA Mutation Assessment in HR+/HER2-Metastatic Breast Cancer: Overview for Oncology Clinical Practice
Criscitiello, Carmen
Marra, Antonio
Curigliano, Giuseppe
JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (01): : 42 - 54
[8] Distinct early proliferation response to neoadjuvant anti-HER2 antibody drug conjugate ± endocrine therapy in early breast cancer in the WSG ADAPT HER2+/HR+ trial
Gluz, Oleg
Nitz, Ulrike
Sherko, Kuemmel
Stefan, Kraemer
Braun, Michael
Schumacher, Claudia
Aktas, Bahriye
Forstbauer, Helmut
Reimer, Toralf
Fasching, Peter
Potenberg, Jochem
Hofmann, Daniel
Kates, Ronald E.
Wuerstlein, Rachel
Christgen, Matthias
Kreipe, Hans H.
Harbeck, Nadia
CANCER RESEARCH, 2015, 75
[9] The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)
Harbeck, N.
Nitz, U. A.
Matthias, C.
Kates, R.
Braun, M.
Kummel, S.
Schumacher, C.
Potenberg, J.
Kraemer, S.
Kleine-Tebbe, A.
Augustin, D.
Aktas, B.
Forstbauer, H.
Tio, J.
Liedtke, C.
Grischke, E-M
de Haas, S. L.
Deurloo, R.
Schumacher, J.
Wuerstlein, R.
Kreipe, H. H.
Gluz, O.
CANCER RESEARCH, 2017, 77
[10] PIK3CA mutational status in tissue & plasma as a prognostic tool in HR+/HER2-breast cancer (BC)
Brage, Eduardo Teran
Mejorada, Rebeca Lozano
Francoso, Aline Rodrigues
Leon, Jose Antonio Munoz
Gutierrez, Alvaro Lopez
Figuero-Perez, Luis
Araujo, Daniel Morchon
Martinez, Maria Garijo
Ruiz, Jonnathan Roldan
Hernandez, Maria Mar Abad
de Salas, Magdalena Sancho
Sanchez, Emilio Fonseca
Sanchez, Cesar Augusto Rodriguez
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →